Results 11 to 20 of about 2,073 (215)

Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision‐Makers [PDF]

Health Economics, 2014
The Institute for Quality and Efficiency in Health Care (IQWiG) developed-in a consultation process with an international expert panel-the efficiency frontier (EF) approach to satisfy a range of legal requirements for economic evaluation in Germany's statutory health insurance system.
Stollenwerk, Björn, Lhachimi, Stefan K., Briggs, Andrew, Fenwick, Elisabeth, Caro, Jaime J., Siebert, Uwe, Danner, Marion, Gerber-Grote, Andreas   +7 more
openaire   +7 more sources

Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment – a systematic review and network meta-analysis [PDF]

BMC Neurology
Background Comparative assessments of all available disease-modifying therapies (DMTs) in patients with highly active relapsing-remitting multiple sclerosis (RRMS) are lacking, even though some of these DMTs are restricted to this MS subpopulation.
Michael Köhler, Friedemann Paul, Kirsten Janke, Sibylle Sturtz, Daniela Preukschat, Sabine Ostlender, Michaela Florina Kerekes, Thomas Kaiser   +7 more
doaj   +2 more sources

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree [PDF]

Health Economics Review, 2019
Background The purpose of this study was to analyse the impact of commissioned addenda by the Federal Joint Committee (FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors of FJC ...
C. M. Dintsios, F. Worm, J. Ruof, M. Herpers   +3 more
doaj   +2 more sources

Acceptability of external control-arm use in nononcology health technology assessment submissions [PDF]

Journal of Comparative Effectiveness Research
Aim: This study assessed the acceptability of external control-arm (ECA) use in nononcology health technology assessment (HTA) submissions in Europe. Materials & methods: We conducted a sequential mixed method study to investigate the study objective ...
Kamal Kant Mangla, Spyros Kolovos, Ana Lisica, Max Schlueter, Nick Fabrin Nielsen   +4 more
doaj   +2 more sources

Höchstmöglicher ESMO-Wert vs. kein Zusatzznutzen [PDF]

Monitor Versorgungsforschung
Im Titelinterview mit „Monitor Versorgungsforschung“ (02/25) ging Dr. med. Thomas Kaiser, Institutsleiter des IQWiG, kurz auf die Nutzenbewertung des Wirkstoffs Pembrolizumab und des MSD-Arznemittels „Keytruda“ ein (1): Auf die Frage „Wie kommt es, dass ...
Peter Stegmaier
doaj   +2 more sources

Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health Technology Assessment Model? [PDF]

INNOVATIONS in Pharmacy, 2017
The contribution of cost-effectiveness analysis to the pricing of pharmaceuticals in Germany is at best marginal and in many, if not most cases, absent.
Paul C Langley
doaj   +4 more sources

Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework [PDF]

Medical Decision Making, 2016
Background. The National Institute for Quality and Efficiency in Health Care (IQWiG) employs an efficiency frontier (EF) framework to facilitate setting maximum reimbursable prices for new interventions. Probabilistic sensitivity analysis (PSA) is used when yes/no reimbursement decisions are sought based on a fixed threshold. In the IQWiG framework, an
Corro Ramos, Isaac, Lhachimi, Stefan K, Gerber-Grote, Andreas, Al, Maiwenn   +3 more
openaire   +4 more sources

Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study [PDF]

Patient Preference and Adherence, 2018
Vera Vennedey,1 Sonja HM Derman,2 Mickaël Hiligsmann,3 Daniele Civello,1 Anja Schwalm,4 Astrid Seidl,4 Fülöp Scheibler,5 Stephanie Stock,1 Michael J Noack,2 Marion Danner1,5 1Institute for Health Economics and Clinical Epidemiology ...
Vennedey V, Derman SHM, Hiligsmann M, Civello D, Schwalm A, Seidl A, Scheibler F, Stock S, Noack MJ, Danner M   +9 more
doaj   +1 more source

Correction: Performance of several types of beta-binomial models in comparison to standard approaches for meta-analyses with very few studies [PDF]

BMC Medical Research Methodology
Moritz Felsch, Lars Beckmann, Ralf Bender, Oliver Kuss, Guido Skipka, Tim Mathes   +5 more
doaj   +2 more sources

Single-fraction stereotactic radiosurgery versus microsurgical resection for the treatment of vestibular schwannoma: a systematic review and meta-analysis

Systematic Reviews, 2022
Background Vestibular schwannomas are benign tumours for which various treatments are available. We performed a systematic review of prospective controlled trials comparing the patient-relevant benefits and harms of single-fraction stereotactic ...
Thomas Jakubeit, Sibylle Sturtz, Dorothea Sow, Wolfram Groß, Christoph Mosch, Mattea Patt, Vera Weingärtner, Jan Boström, Roland Goldbrunner, Martina Markes   +9 more
doaj   +1 more source